Intelligence Feed event · Policy · 2026-10-19

    Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO

    Question

    Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO

    Direct answer

    Roche announced presentation of late-stage oncology trial readouts at ESMO 2026. The dataset includes Phase III confirmation of divarasib outperforming first-generation KRAS G12C targeting drugs in non-small cell lung cancer. Additionally, Roche reported Phase III efficacy results for giredestrant in breast cancer without degrading quality of life, alongside clinical data supporting Tam-Peli in nasopharyngeal indications, bolstering its late-stage pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO”, revision 1, evidence through 2026-10-19. https://marketontology.com/market-events/2026-10-19/roche-presents-pivotal-phase-iii-data-for-divarasib-and-giredestrant-at-esmo-20d0fe

    POLICY
    Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO
    Roche announced presentation of late-stage oncology trial readouts at ESMO 2026. The dataset includes Phase III confirmation of divarasib outperforming first-generation KRAS G12C targeting drugs in non-small cell lung cancer. Additionally, Roche reported Phase III efficacy results for giredestrant in breast cancer without degrading quality of life, alongside clinical data supporting Tam-Peli in nasopharyngeal indications, bolstering its late-stage pipeline.
    RHHBY
    Impact
    72
    OCT 19
    SIG
    85%
    RHHBY
    Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO
    Roche announced presentation of late-stage oncology trial readouts at ESMO 2026. The dataset includes Phase III confirmation of divarasib outperforming first-generation KRAS G12C targeting drugs in non-small cell lung cancer. Additionally, Roche reported Phase III efficacy results for giredestrant in breast cancer without degrading quality of life, alongside clinical data supporting Tam-Peli in nasopharyngeal indications, bolstering its late-stage pipeline.
    → Demonstrated Phase III superiority over existing KRAS G12C therapies accelerates future commercial approval timelines for Roche oncology franchises.
    Impact
    Roche announced presentation of late-stage oncology trial readouts at ESMO 2026. The dataset includes Phase III confirmation of divarasib outperforming first-generation KRAS G12C targeting drugs in non-small cell lung cancer. Additionally, Roche reported Phase III efficacy results for giredestrant in breast cancer without degrading quality of life, alongside clinical data supporting Tam-Peli in nasopharyngeal indications, bolstering its late-stage pipeline.
    Affected
    RHHBY
    Transmission
    Demonstrated Phase III superiority over existing KRAS G12C therapies accelerates future commercial approval timelines for Roche oncology franchises.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RHHBYexpanded addressable market in lung and breast cancer indicationsUp1-4wPhase III data showed divarasib superiority over first-generation KRAS G12C inhibitors and improved efficacy for giredestrant.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month